elderly

Treatment approaches for fit and frail multiple myeloma patients 1:30
Treatment approaches for fit and frail multiple myeloma patients
Jesús San Miguel • 8 Oct 2020
Dual ABL1 inhibition in elderly ALL: asciminib, dasatinib, prednisone 1:22
Dual ABL1 inhibition in elderly ALL: asciminib, dasatinib, prednisone
Daniel DeAngelo
Immune checkpoint blockade upfront in older AML and HR-MDS 2:33
Immune checkpoint blockade upfront in older AML and HR-MDS
Amer Zeidan • 10 Dec 2019
Idasanutlin and venetoclax in elderly R/R AML 4:18
Idasanutlin and venetoclax in elderly R/R AML
Naval Daver
Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungals 2:57
Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungals
Marina Konopleva • 8 Dec 2019
Temporal patterns among older patients with AML 3:17
Temporal patterns among older patients with AML
Amer Zeidan • 27 Sep 2019
RESONATE-2: Ibrutinib for CLL 5-year follow-up 1:20
RESONATE-2: Ibrutinib for CLL 5-year follow-up
Alessandra Tedeschi • 21 Sep 2019
Varicella zoster virus vaccine for haematological malignancies 1:54
Varicella zoster virus vaccine for haematological malignancies
Per Ljungman • 26 Oct 2019
Mechanistic insights into the resistance to anti-CD38 therapy 4:43
Mechanistic insights into the resistance to anti-CD38 therapy
Torben Plesner
Improving the management of geriatric myeloma 2:40
Improving the management of geriatric myeloma
Ashley Elizabeth Rosko • 1 Jun 2019
Treating high-risk myeloma in the elderly 1:16
Treating high-risk myeloma in the elderly
Ashley Elizabeth Rosko • 1 Jun 2019
Managing myeloma in geriatric patients 1:52
Managing myeloma in geriatric patients
Ashley Elizabeth Rosko
The challenges of treating AML in older patients 2:12
The challenges of treating AML in older patients
Farhad Ravandi
Analyzing AML: novel therapies in review 2:25
Analyzing AML: novel therapies in review
Farhad Ravandi • 1 Dec 2018
Geriatric assessment in multiple myeloma: is it required? 1:30
Geriatric assessment in multiple myeloma: is it required?
Alessandra Larocca • 5 Oct 2018
MRD as a response assessment in elderly multiple myeloma 1:00
MRD as a response assessment in elderly multiple myeloma
Alessandra Larocca • 5 Oct 2018
VJHemOnc VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJHemOnc is intended for healthcare professionals